moderate - Companion animal segment shows resilience during downturns as pet owners prioritize animal health (70% of US households own pets), though discretionary spending on premium products can soften. Food animal segment is more cyclical, tied to livestock commodity prices, feed costs, and global protein demand. Emerging market exposure (20-25% of revenue) creates sensitivity to local GDP growth and currency fluctuations. Overall revenue correlation to GDP is approximately 0.5-0.7x.

Rising rates create modest headwinds through higher debt service costs on $5.5B+ debt load (mix of fixed and floating), though refinancing activity in 2024-2025 has extended maturities. Higher rates also pressure valuation multiples for growth-oriented healthcare stocks. Conversely, rate increases signal economic strength that supports protein consumption and livestock production. Net impact is slightly negative on 100-150bps rate moves.

value - Stock trades at discount to animal health peer Zoetis (EV/EBITDA 17.9x vs 25x+) reflecting turnaround story and integration execution risk. Attracts investors seeking margin expansion narrative, debt paydown, and potential multiple re-rating as operational improvements materialize. Recent 120% one-year return suggests momentum investors have entered, but core thesis remains value-oriented given low single-digit revenue growth and focus on cash flow generation over top-line.